Saturday, July 11, 2026

Drug profile · INN

naldemedine tosylate

naldemedine tosylate (SYMPROIC) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — naldemedine tosylate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

naldemedine tosylate (SYMPROIC) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN naldemedine tosylate
Brand SYMPROIC
Mechanism Mu opioid receptor antagonist
Target Mu-type opioid receptor
Route ORAL
Formulation TABLET

Mechanism of action

Mu opioid receptor antagonist

Primary target: Mu-type opioid receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. alvimopan Mu opioid receptor antagonist
  2. loperamide hydrochloride Mu opioid receptor agonist
  3. methadone hydrochloride Mu opioid receptor agonist
  4. morphine sulfate Mu opioid receptor agonist
  5. oxycodone Mu opioid receptor agonist
  6. oxycodone hydrochloride Mu opioid receptor agonist

Frequently asked questions

What is naldemedine tosylate?

naldemedine tosylate (SYMPROIC) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for naldemedine tosylate?

SYMPROIC is a marketed brand name for naldemedine tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of naldemedine tosylate?

naldemedine tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.